[144] DexCom, Inc. SEC Filing

Rhea-AI Filing Summary

Form 144 filed for DexCom, Inc. (DXCM) proposing the sale of 4,824 common shares through Morgan Stanley Smith Barney on 09/02/2025 on NASDAQ at an aggregate market value of $357,796.08. The filing lists acquisition details for the shares: 3,464 shares received as restricted stock on 03/08/2023, 696 shares acquired via an employee stock purchase plan on 08/30/2019 (cash), and 664 shares from an employee stock purchase plan on 02/28/2020 (cash). The filer states there have been no securities sold in the past three months for the account and affirms no undisclosed material adverse information. The notice identifies the broker and gives the number of shares outstanding as 392,155,265.

Positive

• Clear compliance disclosure under Rule 144 with acquisition dates and payment methods provided
• Broker-dealer execution specified (Morgan Stanley Smith Barney), supporting orderly market handling of the sale
• Filer affirms no undisclosed material adverse information as required by the form

Negative

• None.

Insights

Securities Compliance Analyst

TL;DR: Routine Rule 144 notice disclosing a proposed executive sale via a registered broker, with acquisition dates and payment methods provided.

The filing is a standard Rule 144 disclosure showing a planned disposition of 4,824 common shares through Morgan Stanley Smith Barney with explicit acquisition provenance: restricted stock and ESPP purchases with cash where applicable. The inclusion of acquisition dates and payment types supports compliance with resale conditions under Rule 144. The filer also affirms no undisclosed material adverse information, which is customary for such notices.

Equity Markets Analyst

TL;DR: Small, disclosed sale that is unlikely to be material to shareholders but is properly documented.

The aggregate value reported is $357,796.08 for 4,824 shares, and the filing cites the issuer's outstanding shares figure of 392,155,265. The data provided is sufficient to understand the proposed sale size and its execution channel. The filing contains no mention of accelerated sales or plan-based trading instructions; it simply notifies the market of an intended sale under Rule 144.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	4824	357796.08	392155265	09/02/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/08/2023	Restricted Stock	ISSUER			3464	03/08/2023	Not Applicable
Common	08/30/2019	Employee Stock Purchase Plan	ISSUER			696	08/30/2019	Cash
Common	02/28/2020	Employee Stock Purchase Plan	ISSUER			664	02/28/2020	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does DexCom's (DXCM) Form 144 report?

The filing reports a proposed sale of 4,824 common shares for an aggregate market value of $357,796.08 to be sold on 09/02/2025 on NASDAQ.

Who is the broker handling the proposed sale in the DXCM Form 144?

The broker named is Morgan Stanley Smith Barney LLC, address listed as Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004.

When and how were the shares being sold acquired according to the filing?

Acquisitions listed: 3,464 shares as restricted stock on 03/08/2023, 696 shares via ESPP on 08/30/2019 (cash), and 664 shares via ESPP on 02/28/2020 (cash).

Has the filer sold DexCom securities in the past three months?

The filing states Nothing to Report for securities sold during the past three months.

What representation does the filer make about material information?

By signing, the person represents they do not know any material adverse information about the issuer that has not been publicly disclosed.